Lamotrigine (All indications)

Cardiac septal defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8964
R30358		 Veiby (Lamotrigine) (Controls unexposed, disease free) (Mixed indications), 2014 Cardiac septal throughout pregnancy population based cohort retrospective unexposed, disease free Adjustment: No 1.38 [0.69;2.76] C 8/833   5,400/771,412 5,408 833
ref
S8908
R30104		 Källén (Lamotrigine) (Indications NOS), 2013 Septum defect early pregnancy population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.52 [0.83;2.55] 14/1,084   11,155/1,575,847 11,169 1,084
ref
Total 2 studies 1.46 [0.94;2.26] 16,577 1,917
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Veiby (Lamotrigine) (Controls unexposed, disease free) (Mixed indications), 2014Veiby, 2014 1 1.38[0.69; 2.76]5,40883339%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Källén (Lamotrigine) (Indications NOS), 2013Källén, 2013 2 1.52[0.83; 2.55]11,1691,08461%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.46[0.94; 2.26]16,5771,9170.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Controls unexposed, disease free) (Mixed indications; 2: Lamotrigine) (Indications NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.46[0.94; 2.26]16,5771,9170%NAVeiby (Lamotrigine) (Controls unexposed, disease free) (Mixed indications), 2014 Källén (Lamotrigine) (Indications NOS), 2013 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.46[0.94; 2.26]16,5771,9170%NAVeiby (Lamotrigine) (Controls unexposed, disease free) (Mixed indications), 2014 Källén (Lamotrigine) (Indications NOS), 2013 2 Tags Adjustment   - No  - No 1.38[0.69; 2.76]5,408833 -NAVeiby (Lamotrigine) (Controls unexposed, disease free) (Mixed indications), 2014 1   - Yes  - Yes 1.52[0.87; 2.66]11,1691,084 -NAKällén (Lamotrigine) (Indications NOS), 2013 1 All studiesAll studies 1.46[0.94; 2.26]16,5771,9170%NAVeiby (Lamotrigine) (Controls unexposed, disease free) (Mixed indications), 2014 Källén (Lamotrigine) (Indications NOS), 2013 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.46[0.94; 2.26]16,5771,9170%NAVeiby (Lamotrigine) (Controls unexposed, disease free) (Mixed indications), 2014 Källén (Lamotrigine) (Indications NOS), 2013 20.510.01.0